Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.32 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9160306 | 1.00 | ALDH1A1 (0.33) | ALDH1A1TDP1USP2HTTEPHX1 | |
| SCHEMBL30028753 | 0.98 | ALDH1A1 (0.36) | ALDH1A1TDP1USP2HTTEPHX1 | |
| SCHEMBL8496317 | 0.98 | ALDH1A1 (0.36) | ALDH1A1TDP1USP2HTTEPHX1 | |
| SCHEMBL9349040 | 0.98 | ALDH1A1 (0.36) | ALDH1A1TDP1USP2HTTEPHX1 | |
| SCHEMBL31190500 | 0.98 | ALDH1A1 (0.36) | ALDH1A1TDP1USP2HTTEPHX1 | |
| SCHEMBL17844871 | 0.89 | MEN1 (0.31) | ALDH1A1HTT | |
| SCHEMBL8075279 | 0.85 | MAPT (0.34) | — | |
| SCHEMBL29087903 | 0.84 | MEN1 (0.33) | — | |
| SCHEMBL29087905 | 0.84 | MEN1 (0.33) | — | |
| SCHEMBL14764913 | 0.83 | ALDH1A1 (0.33) | ALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040077728-A1 | Retiferol derivatives and their use in the treatment of skin diseases or conditions associated with photodamage | F. HOFFMANN-LA ROCHE AG (CH) | 2004-04-22 | — | — | US | disclosed |
| EP-1341745-A1 | RETIFEROL DERIVATIVES AND THEIR USE IN THE TREATMENT OF SKIN DISEASES OR CONDITIONS ASSOCIATED WITH PHOTODAMAGE | F.HOFFMANN-LA ROCHE AG (CH) | 2003-09-10 | — | — | EP | disclosed |
| WO-2002042247-A1 | RETIFEROL DERIVATIVES AND THEIR USE IN THE TREATMENT OF SKIN DISEASES OR CONDITIONS ASSOCIATED WITH PHOTODAMAGE | F.HOFFMANN-LA ROCHE AG (CH) | 2002-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077728-A1 | Retiferol derivatives and their use in the treatment of skin diseases or conditions associated with photodamage | NR1H2, RFC2, RFC1 | ALDH1A1 2318/4885TDP1 1687/4885USP2 1644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.